Literature DB >> 27332908

Fine-Tuning the Treatment of Hodgkin's Lymphoma.

Nancy L Bartlett1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27332908     DOI： 10.1056/NEJMe1604026

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  3 in total

1.  Cost-Effectiveness Analysis of Brentuximab Vedotin With Chemotherapy in Newly Diagnosed Stage III and IV Hodgkin Lymphoma.

Authors:  Scott F Huntington; Gottfried von Keudell; Amy J Davidoff; Cary P Gross; Sapna A Prasad
Journal:  J Clin Oncol       Date:  2018-10-04       Impact factor: 44.544

2.  Hodgkin lymphoma: A complex metabolic ecosystem with glycolytic reprogramming of the tumor microenvironment.

Authors:  Lekha Mikkilineni; Diana Whitaker-Menezes; Marina Domingo-Vidal; John Sprandio; Paola Avena; Paolo Cotzia; Alina Dulau-Florea; Jerald Gong; Guldeep Uppal; Tingting Zhan; Benjamin Leiby; Zhao Lin; Barbara Pro; Federica Sotgia; Michael P Lisanti; Ubaldo Martinez-Outschoorn
Journal:  Semin Oncol       Date:  2017-10-10       Impact factor: 4.929

3.  ASH2L drives proliferation and sensitivity to bleomycin and other genotoxins in Hodgkin's lymphoma and testicular cancer cells.

Authors:  Daniel Constantin; Christian Widmann
Journal:  Cell Death Dis       Date:  2020-11-30       Impact factor: 8.469
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.